ADVFN Logo
Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

EPIX ESSA Pharma Inc

6.57
0.17 (2.66%)
After Hours
Last Updated: 16:07:32
Delayed by 15 minutes

Period:

Draw Mode:

Volume 130,486
Bid Price 5.65
Ask Price 7.19
News -
Day High 7.25

Low
2.56

52 Week Range

High
11.67

Day Low 6.40
Company Name Stock Ticker Symbol Market Type
ESSA Pharma Inc EPIX NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
0.17 2.66% 6.57 16:07:32
Open Price Low Price High Price Close Price Prev Close
6.46 6.40 7.25 6.57 6.40
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
1,149 130,486 $ 6.74 $ 880,075 - 2.56 - 11.67
Last Trade Time Type Quantity Stock Price Currency
16:00:00 1,726 $ 6.40 USD

ESSA Pharma Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
290.64M 44.24M - 0 -26.58M -0.60 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

ESSA Pharma News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No EPIX Message Board. Create One! See More Posts on EPIX Message Board See More Message Board Posts

Historical EPIX Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week7.327.606.186.5360,869-0.75-10.25%
1 Month9.089.236.187.8060,591-2.51-27.64%
3 Months8.5311.676.189.36128,100-1.96-22.98%
6 Months4.0411.673.807.33143,7412.5362.62%
1 Year2.7711.672.566.06107,3993.80137.18%
3 Years26.1336.001.406.53491,288-19.56-74.86%
5 Years2.4636.001.407.62334,1464.11167.07%

ESSA Pharma Description

ESSA Pharma Inc is a pharmaceutical company. The company is in the preclinical stage, focused on the development of small molecule drugs for the treatment of castration-resistant prostate cancer. The company is developing drugs that selectively block the amino-terminal domain of the androgen receptor, potentially overcoming the known AR-dependent resistance mechanisms of CRPC and providing CRPC patients with the potential for increased progression-free and overall survival.

Your Recent History

Delayed Upgrade Clock